AstraZeneca is hoping a new formulation of Bydureon will give the med some competitive firepower against a field of tough rivals.
Sanofi launched a new corporate signature last week summing up its mission in two words: “Empowering Life," along with a global digital campaign.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
Salix Pharmaceuticals' research found that many people who might have IBS are undiagnosed, leading to a show about IBS-D on the Lifetime Channel.
GlaxoSmithKline has the official go-ahead for its next big launch, the $1 billion vaccine prospect Shingrix.
New Jersey is targeting a doctor for his role in Insys' alleged cash-for-scripts scheme—and it aims to curb pharma's doctor payments, too.
Still struggling to turn its manufacturing around, Dr. Reddy's is recalling 569,000 store-brand famotidine tablets in the U.S.
Here’s a sentence Bristol-Myers Squibb should be used to by now: England’s cost watchdogs have decided not to back routine NHS coverage of Opdivo.
When the year began, the prospect of U.S. tax reform had pharma companies salivating for some M&A action. But so far, that hasn't happened.
AZ and Chi-Med scores early data for savolitinib combos in lung cancer, WuXi AppTec buys a U.S. CRO, FDA clears Sun's Dadra plant.
Merck & Co. plans to jettison three U.S. sales teams and 1,800 associated staffers while creating a new, 960-employee chronic care force.